Research news from the American Diabetes Association 80th Scientific Sessions

The Medtronic MiniMed Advanced Hybrid Closed-Loop system delivers better glycemic control than the currently approved 670G system, shows the international FLAIR trial.

The Youth Empowerment Skills program, a novel psychoeducational intervention for adolescents and young adults with type 1 diabetes, may help to improve glycemic control and reduce acute diabetes emergencies in this challenging group of patients, research shows.

The Omnipod Horizon closed-loop system has delivered good glucose control in its first outpatient study, the investigators report.

A substantial proportion of people with diabetes experience negative psychologic consequences, and these issues are predicted by a number of factors including gaps in person-centered care, insulin use, and complications, suggest findings from a Danish national survey.

A rural telehealth program designed to fit with existing staff and equipment delivers large benefits for people with poorly controlled type 2 diabetes, researchers report.

The selective sodium-glucose cotransporter 2 inhibitor bexagliflozin significantly lowers glycated hemoglobin, weight, and blood pressure relative to placebo in people with type 2 diabetes at high risk for cardiovascular events, phase 3 study findings show.

A post-hoc analysis of data from the CREDENCE trial suggests that transient drops in estimated glomerular filtration rate occur in almost half of canagliflozin-treated patients and are not associated with an increased risk for adverse outcomes.

A 1-year extension of the GOLD study shows that people with type 1 diabetes taking insulin via multiple daily injections retain the glycemic control benefits of continuous glucose monitoring over the long term.

Icosapent ethyl reduces the risk for first and total cardiovascular events in statin-treated patients with diabetes, suggests a subgroup analysis of the REDUCE-IT trial.

Real-world data presented at the virtual ADA 80th Scientific Sessions highlight the benefits of the FreeStyle Libre continuous glucose monitoring system in reducing acute complications in people with type 1 or type 2 diabetes.

Improved diabetes knowledge and reduced distress both contribute to the positive effects of diabetes distress interventions on glycemic outcomes, say researchers.

Findings from the SEARCH for Diabetes in Youth study suggest that diastolic dysfunction is prevalent among young adults with type 1 or type 2 diabetes, but those with type 2 diabetes have the highest risk.

Treatment with canagliflozin is associated with a reduction in the risk for both first and total heart failure events in people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.

Incorrect perception of diabetes patients’ literacy and numeracy by healthcare providers is associated with poor glycemic control, research suggests.

Two small studies reported at the virtual ADA 80th Scientific Sessions have demonstrated positive effects of SGLT2 inhibitors on the liver.

A post-hoc analysis of the EMPA-REG OUTCOME trial shows the first benefits of empagliflozin appearing within the third week of taking the sodium-glucose cotransporter 2 inhibitor.

Impaired awareness of hypoglycemia is associated with an increased risk for severe hypoglycemia and increased fear of hypoglycemia in pregnant women with type 1 diabetes, shows a post-hoc analysis of CONCEPTT data.

Findings from the SEED trial provide further evidence to suggest that the dual-acting glucokinase activator dorzagliatin improves glycemic control compared with placebo and has a favorable safety profile in people with type 2 diabetes.

The SGLT2 inhibitor dapagliflozin reduces the risk for type 2 diabetes by a third in people with heart failure with reduced ejection fraction, particularly those with prediabetes, shows an analysis of data from the DAPA-HF trial.

Study results presented at the virtual ADA 80th Scientific Sessions suggest that a substantial proportion of people with type 2 diabetes have islet autoimmunity, and those with T cell-mediated autoimmunity may represent a distinct subgroup with diminished beta-cell function.